Insulin secretion is a strong predictor for need of insulin therapy in patients with new‐onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study
Diabetes Obesity and Metabolism2021Vol. 23(7), pp. 1631–1639
Citations Over Time
Siham Abdelgani, Curtiss Puckett, John M. Adams, Curtis Triplitt, Ralph A. DeFronzo, Muhammad Abdul‐Ghani
Abstract
Insulin secretion in response to a 75-g OGTT predicts the need for insulin therapy at the time of type 2 diabetes (T2D) diagnosis. A cut point of 1.7 of CPEP120 /CPEP0 provides a useful clinical tool to individualize glucose-lowering therapy in patients with new-onset T2D and HbA1c of more than 10%.
Related Papers
- → Exenatide compared with long‐acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long‐Acting insulin (HEELA) study(2009)148 cited
- Effects of pioglitazone and glipizide on platelet function in patients with type 2 diabetes.(2015)
- → Combination exenatide–sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus(2012)4 cited
- → PDB5 IMPROVED TREATMENT SATISFACTION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE OR INSULIN GLARGINE(2005)1 cited
- → Clinical characteristics and outcomes in patients with type 2 diabetes adding insulin glargine to exenatide or exenatide to insulin glargine in a US managed care setting(2011)